Research programme: anti-CD55 monoclonal antibodies - ViragenAlternative Names: CD55 cancer vaccine - Viragen Scotland; CD55 vaccine - Viragen Scotland; VG 102
Latest Information Update: 04 Feb 2008
At a glance
- Originator Cancer Research Technology; University of Nottingham
- Developer Viragen Scotland
- Class Monoclonal antibodies
- Mechanism of Action CD55 antigen inhibitors; Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer